tirzepatide gip/glp-1 Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Understanding GLP-1 vs. GIP Medications:

Clinical outcomes were assessed using Aberrant Behavior Checklist - Community (ABC-C) at baseline, week 5, and week 10, with no biological or imaging analyses performed

Trustpilot flags occasional warm-vial incidents

The forward-looking statements contained in this communication are made only as of March 18, 2026

Wegovys injection starts at 0.25 mg weekly and titrates up over 16 weeks to the maintenance dose of 2.4 mg weekly

Breastfeeding considerations are complex, as there is insufficient data regarding the presence of these medications in human milk or their effects on the breastfed infant

Diabetes Metab Syndr Obes